The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
Open accessAbstract
The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis. Introduction: RANKL is an essential osteoclastic differentiation and activation factor. Materials and Methods: The bone antiresorptive activity and safety of AMG 162, a fully human monoclonal antibody to RANKL, were evaluated in postmenopausal women in this randomized, double-blind, placebo-controlled, single-dose, dose escalation study. Six cohorts of eight to nine women were randomly assigned to receive a single subcutaneous injection of either AMG 162 or placebo (3:1 ratio). AMG 162 doses were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg. Subjects were followed up to 6 months in all cohorts and 9 months in the three highest dose cohorts. Second morning void urinary N-telopeptide/creatinine (NTX; Osteomark), serum NTX, and serum bone-specific alkaline phosphatase (BALP, Ostase) were assessed as bone turnover markers. Results and Conclusions: Forty-nine women were enrolled. A single subcutaneous dose of AMG 162 resulted in a dose-dependent, rapid (within 12 h), profound (up to 84%), and sustained (up to 6 months) decrease in urinary NTX. At 6 months, there was a mean change from baseline of −81% in the 3.0 mg/kg AMG 162 group compared with −10% in the placebo group; serum NTX changes were −56% and 2%, respectively. BALP levels did not decrease remarkably until after 1 month, indicating that the effect of AMG 162 is primarily antiresorptive. Intact parathyroid hormone (PTH) levels increased up to ∼3-fold after 4 days in the 3.0 mg/kg dose group, but returned toward baseline with follow-up. Albumin-adjusted serum calcium did not decrease >10% on average in any group, and no subject had values below 2 mmol/liter. AMG 162 was well tolerated. No related serious adverse events occurred. No clinically meaningful laboratory changes, other than those described above, were observed. In summary, a single subcutaneous dose of AMG 162 resulted in a dose-dependent rapid and sustained decrease from baseline in bone turnover and could be an effective and convenient treatment for osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 2×
“Genetic experiments have shown that mice with a disrupted RANKL gene have severe osteopetrosis and absence of osteoclasts.((5)) As a soluble member of the TNF receptor family, osteoprotegerin (OPG) blocks bone resorption by binding to RANKL and preventing its interaction with RANK, a cell surface receptor on pre-osteo…”
BackgroundSelf-citationIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Self-citationA homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Self-citationOsteoblast-Osteoclast Communication and Bone Homeostasis
Kim, J.-M., Lin, C., Stavre, Z., Greenblatt, M. B., & Shim, J.-H. (2020) · Cells · doi:10.3390/cells9092073 · Cited by 1,178
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069
“By contrast, the anti-RANK-L monoclonal antibody AMG162, when injected every 6 months, inhibits resorption and increases bone mineral density with similar efficacy to alendronat”
BackgroundBone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Hypercalcemia Associated with Cancer
Stewart, A. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042806 · Cited by 973
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
Thomas, D., Henshaw, R., Skubitz, K., Chawla, S., Staddon, A., Blay, J.-Y., Roudier, M., Smith, J., Ye, Z., Sohn, W., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70010-3 · Cited by 716
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Brown, J. P., Prince, R. L., Deal, C., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro-Gracia, J. M., Wang, H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 610
Cohen, S. B., Dore, R. K., Lane, N. E., Ory, P. A., Peterfy, C. G., Sharp, J. T., van der Heijde, D., Zhou, L., Tsuji, W., Newmark, R., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23417 · Cited by 576
An overview of the regulation of bone remodelling at the cellular level
Kular, J., Tickner, J., Chim, S. M., & Xu, J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.021 · Cited by 534
Fizazi, K., Lipton, A., Mariette, X., Body, J.-J., Rahim, Y., Gralow, J. R., Gao, G., Wu, L., Sohn, W., & Jun, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2146 · Cited by 533
Kostenuik, P. J., Nguyen, H. Q., McCabe, J., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L., Cattley, R. C., Van, G., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081112 · Cited by 443
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & San Martin, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 425
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.-J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8604 · Cited by 389
The Cellular and Molecular Biology of Periprosthetic Osteolysis
Purdue, P. E., Koulouvaris, P., Potter, H. G., Nestor, B. J., & Sculco, T. P. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000238813.95035.1b · Cited by 372
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
Bezooijen, R. L. V., Dijke, P. T., Papapoulos, S. E., & G.M. Löwik, C. W. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.02.005 · Cited by 367
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
The role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
A single-dose study of denosumab in patients with various degrees of renal impairment
Block, G. A., Bone, H. G., Fang, L., Lee, E., & Padhi, D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1613 · Cited by 340
(2007) · PubMed · Cited by 337
Osteoblast physiology in normal and pathological conditions
Neve, A., Corrado, A., & Cantatore, F. P. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1086-1 · Cited by 331
Lewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319
Tanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
The Biology of Aseptic Osteolysis
Holt, G., Murnaghan, C., Reilly, J., & Meek, R. M. D. (2007) · Clinical Orthopaedics & Related Research · doi:10.1097/blo.0b013e31804b4147 · Cited by 319
Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options
de Lange, J., van den Akker, H. P., & van den Berg, H. (2007) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2007.04.003 · Cited by 304
Noncanonical NF-κB Signaling in Health and Disease
Cildir, G., Low, K. C., & Tergaonkar, V. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.002 · Cited by 301
M-CSF mediates TNF-induced inflammatory osteolysis
Kitaura, H. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26132 · Cited by 292
on behalf of the DAPS Investigators, Freemantle, N., Satram-Hoang, S., Tang, E.-T., Kaur, P., Macarios, D., Siddhanti, S., Borenstein, J., & Kendler, D. L. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1780-1 · Cited by 288
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
Design of effective immunotherapy for human autoimmunity
Feldmann, M., & Steinman, L. (2005) · Nature · doi:10.1038/nature03727 · Cited by 277
Osteonecrosis of the Jaw in a Patient on Denosumab
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.10.010 · Cited by 275
The Central Role of Wear Debris in Periprosthetic Osteolysis
Purdue, P. E., Koulouvaris, P., Nestor, B. J., & Sculco, T. P. (2006) · HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-006-9003-6 · Cited by 258
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
Eastell, R., Christiansen, C., Grauer, A., Kutilek, S., Libanati, C., McClung, M. R., Reid, I. R., Resch, H., Siris, E., Uebelhart, D., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.251 · Cited by 256
Bone, H. G., Chapurlat, R., Brandi, M.-L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Mellström, D., Radominski, S. C., Reginster, J.-Y., Resch, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1597 · Cited by 254
Clines, G. A., & Guise, T. A. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00543 · Cited by 253
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
(2005) · PubMed · Cited by 135
New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?
Tat, S. K., Pelletier, J.-P., Velasco, C. R., Padrines, M., & Martel-Pelletier, J. (2009) · The Keio Journal of Medicine · doi:10.2302/kjm.58.29 · Cited by 112
Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1844-1 · Cited by 98
“In prior in vitro and animal studies, OPG has been shown to reduce or prevent increased bone resorption [2, 3]. Both OPG [4] and RANKL antibody [ 5 ] administration to humans have been demonstrated to cause marked decreases in bone resorption.”
BackgroundRANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis
Kim, H. K., Morgan-Bagley, S., & Kostenuik, P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060905 · Cited by 89
Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77
Tat, S. K., Padrines, M., Theoleyre, S., Couillaud-Battaglia, S., Heymann, D., Redini, F., & Fortun, Y. (2006) · Bone · doi:10.1016/j.bone.2006.03.016 · Cited by 63
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
Cremasco, V., Graham, D. B., Novack, D. V., Swat, W., & Faccio, R. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23757 · Cited by 51
Reginster, J. Y., Neuprez, A., Beaudart, C., Lecart, M. P., Sarlet, N., Bernard, D., Disteche, S., & Bruyere, O. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0179-z · Cited by 29
Jörg, D. J., Fuertinger, D. H., Cherif, A., Bushinsky, D. A., Mermelstein, A., Raimann, J. G., & Kotanko, P. (2022) · eLife · doi:10.7554/elife.76228 · Cited by 15
Metadata
- Authors
- Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 19
- Issue
- 7
- Pages
- 1059-1066
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2048346627
- Cited by
- 771
- References
- 50
- FWCI
- 47.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.